Skip to content 
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. more
| Time Frame | LLY | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -1.22% | -1.4% | -1.21% |
| 1-Month Return | -4.53% | -4.04% | -2.04% |
| 3-Month Return | -5.06% | -1.81% | -0.35% |
| 6-Month Return | 30.13% | 10.07% | 1.5% |
| 1-Year Return | 19.93% | 2.89% | 17.99% |
| 3-Year Return | 200.48% | 19.98% | 70.94% |
| 5-Year Return | 429.71% | 31.43% | 68.43% |
| 10-Year Return | 1332.26% | 127.77% | 227.66% |
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 28.32B | 28.54B | 34.12B | 45.04B | 65.18B | [{"date":"2021-12-31","value":43.45,"profit":true},{"date":"2022-12-31","value":43.79,"profit":true},{"date":"2023-12-31","value":52.35,"profit":true},{"date":"2024-12-31","value":69.11,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Cost of Revenue | 7.31B | 6.63B | 7.08B | 8.42B | 10.56B | [{"date":"2021-12-31","value":69.22,"profit":true},{"date":"2022-12-31","value":62.76,"profit":true},{"date":"2023-12-31","value":67.04,"profit":true},{"date":"2024-12-31","value":79.69,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Profit | 21.01B | 21.91B | 27.04B | 36.62B | 54.62B | [{"date":"2021-12-31","value":38.46,"profit":true},{"date":"2022-12-31","value":40.12,"profit":true},{"date":"2023-12-31","value":49.51,"profit":true},{"date":"2024-12-31","value":67.06,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Gross Margin | 74.18% | 76.77% | 79.25% | 81.31% | 83.79% | [{"date":"2021-12-31","value":88.52,"profit":true},{"date":"2022-12-31","value":91.62,"profit":true},{"date":"2023-12-31","value":94.57,"profit":true},{"date":"2024-12-31","value":97.04,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Expenses | 13.07B | 13.26B | 16.25B | 19.12B | 24.92B | [{"date":"2021-12-31","value":52.46,"profit":true},{"date":"2022-12-31","value":53.21,"profit":true},{"date":"2023-12-31","value":65.23,"profit":true},{"date":"2024-12-31","value":76.74,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Operating Income | 7.93B | 8.65B | 10.79B | 17.50B | 29.70B | [{"date":"2021-12-31","value":26.71,"profit":true},{"date":"2022-12-31","value":29.14,"profit":true},{"date":"2023-12-31","value":36.33,"profit":true},{"date":"2024-12-31","value":58.94,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Total Non-Operating Income/Expense | (2.09B) | (2.12B) | (4.54B) | (5.43B) | - | [{"date":"2021-12-31","value":-209190000000,"profit":false},{"date":"2022-12-31","value":-211570000000,"profit":false},{"date":"2023-12-31","value":-454500000000,"profit":false},{"date":"2024-12-31","value":-542670000000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}] |
| Pre-Tax Income | 6.16B | 6.81B | 6.55B | 12.68B | 25.73B | [{"date":"2021-12-31","value":23.92,"profit":true},{"date":"2022-12-31","value":26.45,"profit":true},{"date":"2023-12-31","value":25.47,"profit":true},{"date":"2024-12-31","value":49.28,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income Taxes | 573.80M | 561.60M | 1.31B | 2.09B | 5.09B | [{"date":"2021-12-31","value":11.27,"profit":true},{"date":"2022-12-31","value":11.03,"profit":true},{"date":"2023-12-31","value":25.81,"profit":true},{"date":"2024-12-31","value":41.06,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income After Taxes | 5.58B | 6.24B | 5.24B | 10.59B | - | [{"date":"2021-12-31","value":52.71,"profit":true},{"date":"2022-12-31","value":58.97,"profit":true},{"date":"2023-12-31","value":49.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Income From Continuous Operations | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | [{"date":"2021-12-31","value":27.04,"profit":true},{"date":"2022-12-31","value":30.26,"profit":true},{"date":"2023-12-31","value":25.39,"profit":true},{"date":"2024-12-31","value":51.31,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}] |
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B | [{"date":"2021-12-31","value":27.05,"profit":true},{"date":"2022-12-31","value":30.26,"profit":true},{"date":"2023-12-31","value":25.39,"profit":true},{"date":"2024-12-31","value":51.31,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
| EPS (Diluted) | 8.17 | 8.09 | 6.32 | 13.00 | 24.21 | [{"date":"2021-12-31","value":33.75,"profit":true},{"date":"2022-12-31","value":33.42,"profit":true},{"date":"2023-12-31","value":26.1,"profit":true},{"date":"2024-12-31","value":53.7,"profit":true},{"date":"2025-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| LLY | |
|---|---|
| Cash Ratio | 0.21 |
| Current Ratio | 1.58 |
| Quick Ratio | 1.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| LLY | |
|---|---|
| ROA (LTM) | 19.42% |
| ROE (LTM) | 101.16% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| LLY | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.76 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.24 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| LLY | |
|---|---|
| Trailing PE | 42.92 |
| Forward PE | 28.82 |
| P/S (TTM) | 13.53 |
| P/B | 33.15 |
| Price/FCF | 1301 |
| EV/R | 14.04 |
| EV/Ebitda | 28.87 |
| PEG | 1.06 |
Eli Lilly and Company (LLY) share price today is $930.35
Yes, Indians can buy shares of Eli Lilly and Company (LLY) on Vested. To buy
Yes, you can purchase fractional shares of Eli Lilly and Company (LLY) via the Vested app. You can start investing in Eli Lilly and Company (LLY) with a minimum investment of $1.
You can invest in shares of Eli Lilly and Company (LLY) via Vested in three simple steps:
The 52-week high price of Eli Lilly and Company (LLY) is $1132.06. The 52-week low price of Eli Lilly and Company (LLY) is $620.46.
The price-to-earnings (P/E) ratio of Eli Lilly and Company (LLY) is 42.9229
The price-to-book (P/B) ratio of Eli Lilly and Company (LLY) is 33.15
The dividend yield of Eli Lilly and Company (LLY) is 0.61%
The market capitalization of Eli Lilly and Company (LLY) is $883.28B
The stock symbol (or ticker) of Eli Lilly and Company is LLY
Consider the share price of Eli Lilly and Company as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Eli Lilly and Company has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Eli Lilly and Company shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Eli Lilly and Company stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Eli Lilly and Company and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Eli Lilly and Company stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
